At a glance
Summary
Agilent Technologies closed at 156.47 USD for the week ended 18 September, up 6.5% and only 4.4% below its 52-week high. The move was supported by 13.6M shares, or 1.3x the 13-week average, while the weekly Trend Signal stayed active for an eighth week. The read is constructive but not clean: the stock is down 1.6% over four weeks, trades 20.7% above its Trend Line and carries negative next-week expectancy at 43.76%.
- Agilent rose 6.5% on the week to 156.47 USD, lifting the stock to 86.9% of its 52-week range and 4.4% below its 163.75 USD high.
- Volume improved to 13.6M shares, 1.3x both the 13-week and 52-week averages, giving the rebound moderate participation rather than full confirmation.
- The Trend Signal remains active with an eight-week streak, while price sits 20.7% above the weekly Trend Line and 20.6% above Sharemaestro Fair Value.
- Sector and industry context is supportive, but mixed: US Diagnostics & Research gained 6.0% for the week and has 77.3% trend breadth, while Agilent still trails the industry’s 21.0% 12-week average return.
Company analysis
The move in context
High-range rebound gets moderate volume backing
Agilent Technologies, the Santa Clara-based analytical instrumentation company in the Healthcare sector’s Diagnostics & Research industry, finished the latest week at 156.47 USD, up 6.5%. That put the stock high in its yearly range at 86.9%, just 4.4% under the 52-week high of 163.75 USD and well above the 52-week low of 108.14 USD.
Participation improved with the move. Weekly volume reached 13.6M shares against a 13-week average of 10.7M and a 52-week average of 10.3M, a 1.3x ratio on both measures. That is enough to validate interest in the rebound, although Sharemaestro would treat a stronger participation burst, above roughly 1.5x, as a cleaner confirmation signal.
Trend state is constructive, but the setup is balanced
The weekly Trend Signal remains active and has now been in place for eight weeks. Agilent also holds a wide cushion over the weekly Trend Line at 129.66 USD, with the latest close 20.7% above that regime level. Activity pressure is positive at 1.60, supporting the current market-dynamics read.
The caution is that the stock has already travelled far from its internal reference points. Sharemaestro Fair Value stands at 129.78 USD, leaving Agilent at a 20.6% premium. The composite score of 59 and the “Balanced read” setup reflect that tension: price and volume have improved, but the risk of a pause rises when the stock is near its high with limited valuation cushion.
Sector support is real, but Agilent is not the fastest diagnostics name
Healthcare was broadly supportive, with the sector averaging a 1.2% weekly gain and 69.0% active trend breadth. Diagnostics & Research was stronger, up 6.0% on average for the week, with 77.3% trend breadth and 79.5% positive Market Dynamics breadth. Agilent’s 6.5% weekly gain slightly beat the industry average and ranked well within US Healthcare, at the 84.6th percentile among 941 stocks on peer-relative performance.
The relative comparison is less favourable over longer windows. Agilent’s 12-week return is 15.3%, below the Diagnostics & Research industry average of 21.0%, and its four-week return remains negative at minus 1.6% while the industry is up 3.3%. Relative Strength is positive, but the latest leadership reading has cooled from earlier levels, with the four-week change down 17.1%.
Risk is tied to follow-through near the high
Recent volatility is manageable at 4.0% over 13 weeks versus a 4.8% one-year base, but the return pattern is uneven. Over the 52-week window, Agilent has logged 21 positive weeks and 31 negative weeks. The average up week has been stronger at 5.0% than the average down week at minus 2.5%, which helps explain the stock’s net advance, but the frequency skew still argues for discipline around pullbacks.
What to watch next is whether Agilent can hold the high-range breakout attempt without losing activity pressure. A push through the recent high with heavier volume would strengthen the case for continuation. Failure to build on the 6.5% rebound, especially if volume fades or the stock starts moving back toward the Trend Line, would point to exhaustion rather than fresh accumulation.
Peer comparison
How the wider group is behaving
Breadth shows how much of the sector or industry is participating. A company move is more convincing when its peers are improving too.
US Healthcare
100 tracked companiesAbove Trend Line69.0%
Positive Relative Strength49.0%
US Diagnostics & Research
44 tracked companiesAbove Trend Line77.3%
Positive Relative Strength52.3%
Balanced view
What supports the case, and what could weaken it
What is working
- The trend backdrop is active with a 8-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Activity pressure is constructive, supporting the smart-money activity read.
What needs caution
- Next-week expectancy is negative at 43.76% based on similar historical setup states.
- 3 reversal markers appear in the recent smart-money tape.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/agilent-6-5-week-high-range-volume-fair-value-premium/.
Follow new Sharemaestro research through the RSS feed or JSON feed.